Physician profile

Travis Nesbitt

Oral and Maxillofacial Surgery · Mooresville, NC

NPI 1437532736

$984.44

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Entertainment$353.12
Food and Beverage$225.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Keystone Dental INC. $482.36 2022-2024
Straumann USA LLC $386.68 2022-2024
Geistlich Pharma, North America, INC. $31.54 2024 Geistlich Bio-Gide
Kowa Pharmaceuticals America, INC. $21.60 2023 Seglentis
Henry Schein, INC. $16.84 2024
Masimo Corporation $16.45 2023 Set and Rainbow Set
Zimvie INC. $15.39 2023
Dentsply Sirona INC $13.58 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Travis Nesbitt

$984.44

in general payments reported 2019-2025

Years
2019-2024
Top company
Keystone Dental INC.

https://glasscript.com/doctor/5858864/travis-nesbitt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.